Standardization of multi disciplinary team treatment for breast cancer (2023 edition)

Specialty Construction-Multidisciplinary Expert Committee for Creating Healthy China Energizing; Society of Breast Cancer China Anti-Cancer Association The

doi:10.19401/j.cnki.1007-3639.2023.12.005

您当前的位置：

首页 >

文章列表页 >

Standardization of multi disciplinary team treatment for breast cancer (2023 edition)

Guideline and Concensus | 更新时间：2025-12-31

- Standardization of multi disciplinary team treatment for breast cancer (2023 edition)
- China Oncology Vol. 33, Issue 12, Pages: 1188-1203(2023)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.12.005
  CLC： R737.9
- Received：24 October 2023，
  
  Revised：2023-11-29，
  
  Published：30 December 2023
- 稿件说明：
移动端阅览
Specialty Construction-Multidisciplinary Expert Committee for Creating Healthy China Energizing, Society of Breast Cancer China Anti-Cancer Association The. Standardization of multi disciplinary team treatment for breast cancer (2023 edition)[J]. China Oncology, 2023, 33(12): 1188-1203.
DOI：

Specialty Construction-Multidisciplinary Expert Committee for Creating Healthy China Energizing, Society of Breast Cancer China Anti-Cancer Association The. Standardization of multi disciplinary team treatment for breast cancer (2023 edition)[J]. China Oncology, 2023, 33(12): 1188-1203. DOI： 10.19401/j.cnki.1007-3639.2023.12.005.

摘要

2020年乳腺癌已成为全球发病率最高的恶性肿瘤，近年来随着诊疗技术的提升，中国乳腺癌患者生存率虽显著提高，但仍与西方国家存在较大差异。目前国内乳腺癌诊治仍存在诸多不足的地方，如院内缺少综合治疗的复合型医学人才、患者有效就诊时间短、就诊流程繁琐等。多学科团队诊疗（multidisciplinary team treatment，MDT）模式是由多个学科的资深专家团队合作，针对某一种或某一系统疾病的病例进行讨论，在综合各学科意见的基础上为患者制订出最佳治疗方案的诊疗模式。MDT已经逐渐被多个肿瘤治疗领域接受并广泛实施，很多常见肿瘤治愈率的提高是通过MDT实现的。该模式涉及方面广泛，包括医院制度化建设及核心科室和协同科室的专业合作等。其实施可以提高疾病的诊断率，减少误诊或漏诊，也可以提高指南实施规范性，从而在整体上提高以患者为中心的全病程管理能力及乳腺癌单病种科室的诊疗能力，最终助力《健康中国行动（2019—2030年）》实现。但全国各地MDT实施缺乏统一的流程及标准，国内外尚无专门针对乳腺癌单病种的MDT标准与规范，以指导并提升临床实践能力。本标准与规范由健康报社主办，中国抗癌协会乳腺癌专业委员会发起，在具有肿瘤诊疗相关专科的综合医院和肿瘤专科医院组织多学科专家，依据高级别循证医学依据，通过共同讨论形成赋能专科建设项目并制订《乳腺癌多学科诊疗标准与规范（2023年版）》。本标准与规范的具体内容包括：① 乳腺癌MDT组织建设及运营机制的基本要求；② 初诊（早期）乳腺癌患者MDT标准与规范；③ 复诊（复发转移性/初诊晚期）乳腺癌患者MDT标准与规范；④ 以患者为中心的MDT规范化标准诊疗流程；⑤ 乳腺癌MDT高质量发展的其他要求及建议。本标准与规范旨在从MDT所有参与的单学科或科室应该承担的职责出发，以患者为中心，提供一站式医疗服务，共同探索符合中国国情的MDT标准与规范，同时评选出优秀及标杆医院，以促进该领域的MDT进展，并进一步规范乳腺癌慢病化与规范化全程管理，最终推动乳腺癌领域的变革与进步，造福乳腺癌患者。

Abstract

Breast cancer has become the most common malignant tumor in the world since 2020. With the diagnosis and therapeutic regimens improvement in breast cancer

survival rate of Chinese patients has been significantly enhanced in recent years. However

there is still significant difference in overall survival rate between China and western countries. Many unmet needs exist in daily clinical diagnosis and treatment of breast cancer in China e.g.

shortage of high-quality versatile medical talents

insufficient effectively visiting duration for single patient

overly complicated outpatient or inpatient hospital process. Multidisciplinary team treatment (MDT) is an optimized therapeutic model or platform in which many senior medical experts from multiple disciplines would collaborate together to discuss each single case or each category of cases deeply and thoroughly

and then design the specific treatment plans based on all comprehensive recommendations. MDT has been gradually accepted and widely adopted in multiple anti-cancer therapy

and has somehow largely enhanced the cancer cure rate. The MDT model involves many aspects including hospital system construction

cooperation between core and collaborative departments. MDT can improve disease diagnosis rate

reduce misdiagnosis or missed diagnosis

enhance standardization of clinical guidelines

optimize patient-centered whole disease process management and finally strengthen the therapeutic capabilities for breast cancer as a single disease department

ultimately contributing to the achievement of the goal of 'Healthy China Initiative (2019-2030)' project. However

current reality is the lack of unified standard for MDT execution process in China

and there is no specific MDT guideline for breast cancer globally and domestically which can guide or enhance the daily clinical practice. Hosted by Chinese Health Newspaper and initiated by Breast Cancer Professional Committee of Chinese Anti-Cancer Association

this paper came from joint discussions of multidisciplinary experts from top general and specialized hospitals based on high-level evidence-based medicine. The main contents were as following: ① Basic requirement for hospital or department system construction or operating process for breast cancer MDT; ② Standard and requirement for early-stage breast cancer MDT; ③ Standard and requirement for late-stage breast cancer MDT; ④ Standard and requirement for patient-centered breast cancer MDT; ⑤ Other or further requirements for high-quality breast cancer MDT. Here we discussed the exact responsibility of each department involved in MDT

providing patient-centered and one-stop medical services

and then combined together to explore MDT execution standard which would be suitable for current medical care status in China. Meanwhile we selected the outstanding or benchmark hospitals to push forward MDT model enlargement and enhance whole management process of breast cancer as a chronic disease

ultimately to enhance therapeutic improvement in breast cancer and benefit breast cancer patients..

关键词

Keywords

references

国家卫生计生委办公厅 , 国家中医药管理局办公室 . 关于加强肿瘤规范化诊疗管理工作的通知 [J ] . 中华人民共和国国家卫生和计划生育委员会公报 , 2016 , 3 : 3 - 5 .

The General Office of the Health and Family Planning Commission of the People’s Republic of China , Office of the State Administration of Traditional Chinese Medicine of the People’s Republic of China . Notice on strengthening the standardized diagnosis and treatment management of tumors [J ] . Gazette of the Health and Family Planning Commission of the People's Republic of China , 2016 , 3 : 3 - 5 .

中华人民共和国国务院印发 . “健康中国2030”规划纲要 [J ] . 中华人民共和国国务院公报 , 2016 , 32 : 5 - 20 .

Issued by the State Council of the People's Republic of China . The Outline of the Healthy China 2030 Plan [J ] . Gazette of the State Council of the People’s Republic of China , 2016 , 32 : 5 - 20 .

中华人民共和国国务院 . 国务院关于实施健康中国行动的意见 [N ] . 人民日报 , 2019-07-16.007.

The State Council of the People’s Republic of China . Opinions of the State Council on Implementing the Healthy China Action [N ] . People’s Daily , 2019-07-16.007.

马晓璐 . 健康中国行动(2019—2030年) [J ] . 标准生活 , 2019 ( 8 ): 34 - 41 .

MA X L . Healthy China action (2019-2030) [J ] . Stand Living , 2019 ( 8 ): 34 - 41 .

WHITEHOUSE M . A policy framework for commissioning cancer services [J ] . BMJ , 1995 , 310 ( 6992 ): 1425 - 1426 . DOI: 10.1136/bmj.310.6992.1425 http://doi.org/10.1136/bmj.310.6992.1425

KESSON E M , ALLARDICE G M , GEORGE W D , et al . Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women [J ] . BMJ , 2012 , 344 : e2718 . DOI: 10.1136/bmj.e2718 http://doi.org/10.1136/bmj.e2718 https://www.bmj.com/lookup/doi/10.1136/bmj.e2718 https://www.bmj.com/lookup/doi/10.1136/bmj.e2718

MORRIS E , HAWARD R A , GILTHORPE M S , et al . The impact of the Calman-Hine report on the processes and outcomes of care for Yorkshire’s breast cancer patients [J ] . Ann Oncol , 2008 , 19 ( 2 ): 284 - 291 . DOI: 10.1093/annonc/mdm432 http://doi.org/10.1093/annonc/mdm432 https://linkinghub.elsevier.com/retrieve/pii/S0923753419413240 https://linkinghub.elsevier.com/retrieve/pii/S0923753419413240

国家肿瘤质控中心乳腺癌专家委员会 . 中国乳腺癌规范诊疗质量控制指标(2022版) [J ] . 中华肿瘤杂志 , 2022 , 44 ( 3 ): 203 - 208 .

National Cancer Quality Control Center breast cancer Expert Committee . Quality control index for standardized diagnosis and treatment of breast cancer in China (2022 edition) [J ] . Chin J Oncol , 2022 , 44 ( 3 ): 203 - 208 .

LEI S , ZHENG R , ZHANG S , et al . Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020 [J ] . Cancer Commun (Lond) , 2021 , 41 ( 11 ): 1183 - 1194 .

SAINI K S , TAYLOR C , RAMIREZ A J , et al . Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries [J ] . Ann Oncol , 2012 , 23 ( 4 ): 853 - 859 . DOI: 10.1093/annonc/mdr352 http://doi.org/10.1093/annonc/mdr352

关于印发第一批肿瘤消化系统多学科诊疗试点医院名单的通知(2018) [EB/OL ] . [ 2023 - 09 - 30 ] . http://www.nhc.gov.cn/yzygj/s3593g/201812/eb2e49cbe504464790d922a3f8e7a1d2.shtml http://www.nhc.gov.cn/yzygj/s3593g/201812/eb2e49cbe504464790d922a3f8e7a1d2.shtml http://www.nhc.gov.cn/yzygj/s3593g/201812/eb2e49cbe504464790d922a3f8e7a1d2.shtml .

Notice on issuing the first batch of pilot hospitals for multidisciplinary diagnosis and treatment of cancer digestive system(2018) [EB/OL ] . [ 2023 - 09 - 30 ] . http://www.nhc.gov.cn/yzygj/s3593g/201812/eb2e49c be504464790d922a3f8e7a1d2.shtml http://www.nhc.gov.cn/yzygj/s3593g/201812/eb2e49cbe504464790d922a3f8e7a1d2.shtml http://www.nhc.gov.cn/yzygj/s3593g/201812/eb2e49cbe504464790d922a3f8e7a1d2.shtml .

TAYLOR C , RAMIREZ A . Defining the characteristics of effective MDT working in cancer care [J ] . BMJ Support Palliat Care , 2011 , 1 : A23 -A23.

GUYATT H G , OXMAN D A , VIST E G , et al . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations [J ] . BMJ , 2008 , 336 ( 7650 ): 924 - 826 . DOI: 10.1136/bmj.39489.470347.AD http://doi.org/10.1136/bmj.39489.470347.AD https://www.bmj.com/lookup/doi/10.1136/bmj.39489.470347.AD https://www.bmj.com/lookup/doi/10.1136/bmj.39489.470347.AD

FRIEDMAN E L , CHAWLA N , MORRIS P T , et al . Assessing the development of multidisciplinary care: experience of the national cancer institute community cancer centers program [J ] . J Oncol Pract , 2015 , 11 ( 1 ): e36 - e43 . DOI: 10.1200/JOP.2014.001535 http://doi.org/10.1200/JOP.2014.001535 https://ascopubs.org/doi/10.1200/JOP.2014.001535 https://ascopubs.org/doi/10.1200/JOP.2014.001535

EL SAGHIR N S , KEATING N L , CARLSON R W , et al . Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide [J ] . Am Soc Clin Oncol Educ Book , 2014 : e461 -e466.

KOČO L , SIEBERS C C N , SCHLOOZ M , et al . Mapping current organizational structure and improvement points of breast cancer multidisciplinary team meetings-an interview study [J ] . J Multidiscip Healthc , 2022 , 15 : 2421 - 2430 . DOI: 10.2147/JMDH.S380293 http://doi.org/10.2147/JMDH.S380293 https://www.dovepress.com/mapping-current-organizational-structure-and-improvement-points-of-bre-peer-reviewed-fulltext-article-JMDH https://www.dovepress.com/mapping-current-organizational-structure-and-improvement-points-of-bre-peer-reviewed-fulltext-article-JMDH

WALRAVEN J E W , VAN DER HEL O L , VAN DER HOEVEN J J M , et al . Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review [J ] . BMC Health Serv Res , 2022 , 22 ( 1 ): 829 . DOI: 10.1186/s12913-022-08112-0 http://doi.org/10.1186/s12913-022-08112-0

LU J , JIANG Y , QIAN M , et al . The improved effects of a multidisciplinary team on the survival of breast cancer patients: experiences from China [J ] . Int J Environ Res Public Health , 2019 , 17 ( 1 ): E277 .

CHAN W F , CHEUNG P S , EPSTEIN R J , et al . Multidisciplinary approach to the management of breast cancer in Hong Kong [J ] . World J Surg , 2006 , 30 ( 12 ): 2095 - 2100 . DOI: 10.1007/s00268-005-0370-9 http://doi.org/10.1007/s00268-005-0370-9 https://onlinelibrary.wiley.com/doi/10.1007/s00268-005-0370-9 https://onlinelibrary.wiley.com/doi/10.1007/s00268-005-0370-9

赫捷 , 陈万青 , 李霓 , 等 . 中国女性乳腺癌筛查与早诊早治指南(2021, 北京) [J ] . 中国肿瘤 , 2021 , 30 ( 3 ): 161 - 191 .

HE J , CHEN W Q , LI N , et al . China guideline for the screening and early detection of female breast cancer (2021, Beijing) [J ] . China Cancer , 2021 , 30 ( 3 ): 161 - 191 .

唐振宁 , 刘奇伦 . 多学科协作模式在乳腺癌诊治中的应用 [J ] . 中华乳腺病杂志(电子版) , 2016 , 10 ( 3 ) 177 - 179

TANG Z N , LIU Q L . Application of multidisciplinary cooperation model in diagnosis and treatment of breast cancer [J ] . Chin J Breast Dis Electron Version , 2016 , 10 ( 3 ) 177 - 179

SCHARL A , KÜHN T , PAPATHEMELIS T , et al . The right treatment for the right patient-personalised treatment of breast cancer [J ] . Geburtshilfe Frauenheilkd , 2015 , 75 ( 7 ): 683 - 691 . DOI: 10.1055/s-00000020 http://doi.org/10.1055/s-00000020 http://www.thieme-connect.de/products/ejournals/journal/10.1055/s-00000020 http://www.thieme-connect.de/products/ejournals/journal/10.1055/s-00000020

CHENG Y C , UENO N T . Improvement of survival and prospect of cure in patients with metastatic breast cancer [J ] . Breast Cancer , 2012 , 19 ( 3 ): 191 - 199 . DOI: 10.1007/s12282-011-0276-3 http://doi.org/10.1007/s12282-011-0276-3

ORTMANN O , BLOHMER J U , SIBERT N T , et al . Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94 638 patients treated in 55 breast cancer centers [J ] . J Cancer Res Clin Oncol , 2023 , 149 ( 3 ): 1195 - 1209 . DOI: 10.1007/s00432-022-03938-x http://doi.org/10.1007/s00432-022-03938-x

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-Cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .

《中国乳腺癌新辅助治疗专家共识2022年版》专家组 . 中国乳腺癌新辅助治疗专家共识(2022年版) [J ] . 中国癌症杂志 , 2022 , 32 ( 1 ): 80 - 89 . DOI: 10.19401/j.cnki.1007-3639.2022.01.011 http://doi.org/10.19401/j.cnki.1007-3639.2022.01.011

Expert Group of Expert Consensus on Neoadjuvant Treatment of Breast Cancer in China (2022 edition) . Expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition) [J ] . China Oncol , 2022 , 32 ( 1 ): 80 - 89 .

REN T T , WU J L , QIAN L , et al . Comparison of efficacy and psychology of breast-conserving surgery and modified radical mastectomy on patients with early breast cancer under graded nursing [J ] . Comput Math Methods Med , 2022 , 2022 : 4491573 .

HARRISON J D , CHOY E T , SPILLANE A , et al . Australian breast cancer specialists' involvement in multidisciplinary treatment planning meetings [J ] . Breast , 2008 , 17 ( 4 ): 335 - 340 . DOI: 10.1016/j.breast.2008.03.001 http://doi.org/10.1016/j.breast.2008.03.001

TOI M , TAKADA M . Comments to the Chinese Society of Clinical Oncology (CSCO) breast cancer guidelines 2022 [J ] . Transl Breast Cancer Res , 2022 , 3 : 21 . DOI: 10.21037/tbcr http://doi.org/10.21037/tbcr http://tbcr.amegroups.com http://tbcr.amegroups.com

MCDONALD E S , CLARK A S , TCHOU J , et al . Clinical diagnosis and management of breast cancer [J ] . J Nucl Med , 2016 , 57 ( Suppl 1 ): 9S - 16S . DOI: 10.2967/jnumed.115.157834 http://doi.org/10.2967/jnumed.115.157834 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.115.157834 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.115.157834

BLACKWOOD O , DEB R . Multidisciplinary team approach in breast cancer care: benefits and challenges [J ] . Indian J Pathol Microbiol , 2020 , 63 ( Supplement ): S105 - S112 .

XU B H , HU X C , JIANG Z F , et al . National consensus in China on diagnosis and treatment of patients with advanced breast cancer [J ] . Ann Transl Med , 2015 , 3 ( 17 ): 242 . DOI: 10.3978/j.issn.2305-5839.2015.09.47 http://doi.org/10.3978/j.issn.2305-5839.2015.09.47

邵志敏 , 沈镇宙 , 徐兵河 . 乳腺肿瘤学 [M ] . 上海 : 复旦大学出版社 , 2023 .

SHAO Z M , SHEN Z Z , XU B H . Tumor of the breast [M ] . Shanghai : Fudan University Press , 2023 .

KENT C L , MCDUFF S G R , SALAMA J K . Oligometastatic breast cancer: where are we now and where are we headed? A narrative review [J ] . Ann Palliat Med , 2021 , 10 ( 5 ): 5954 - 5968 . DOI: 10.21037/apm http://doi.org/10.21037/apm http://apm.amegroups.com http://apm.amegroups.com

SWAIN S M , MILES D , KIM S B , et al . Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study [J ] . Lancet Oncol , 2020 , 21 ( 4 ): 519 - 530 . DOI: S1470-2045(19)30863-0 http://doi.org/S1470-2045(19)30863-0

XU B H , LI W , ZHANG Q Y , et al . Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase Ⅲ, randomized, double-blind, placebo-controlled study [J ] . Breast Cancer Res Treat , 2020 , 182 ( 3 ): 689 - 697 . DOI: 10.1007/s10549-020-05728-w http://doi.org/10.1007/s10549-020-05728-w

DIÉRAS V , MILES D , VERMA S , et al . Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial [J ] . Lancet Oncol , 2017 , 18 ( 6 ): 732 - 742 . DOI: S1470-2045(17)30312-1 http://doi.org/S1470-2045(17)30312-1

XU B , YAN M , MA F , et al . LBA19 Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase Ⅲ trial [J ] . Ann Oncol , 2022 , 33 : S1387 .

BLEICH C , BÜSCHER C , MELCHIOR H , et al . Effectiveness of case management as a cross-sectoral healthcare provision for women with breast cancer [J ] . Psychooncology , 2017 , 26 ( 3 ): 354 - 360 . DOI: 10.1002/pon.4139 http://doi.org/10.1002/pon.4139

WANG N N , CHEN J , CHEN W J , et al . The effectiveness of case management for cancer patients: an umbrella review [J ] . BMC Health Serv Res , 2022 , 22 ( 1 ): 1247 . DOI: 10.1186/s12913-022-08610-1 http://doi.org/10.1186/s12913-022-08610-1

BLACKWOOD O , DEB R . Multidisciplinary team approach in breast cancer care: benefits and challenges [J ] . Indian J Pathol Microbiol , 2020 , 63 ( 5 ): 105 . DOI: 10.4103/IJPM.IJPM_885_19 http://doi.org/10.4103/IJPM.IJPM_885_19 http://www.ijpmonline.org/text.asp?2020/63/5/105/279554 http://www.ijpmonline.org/text.asp?2020/63/5/105/279554

AMIR Z , SCULLY J , BORRILL C . The professional role of breast cancer nurses in multi-disciplinary breast cancer care teams [J ] . Eur J Oncol Nurs , 2004 , 8 ( 4 ): 306 - 314 .

Views

7802

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

A study of 30-year trends in incidence and mortality risks of breast cancer among young women in China

Impact of miR-193a-3p on migration and invasion of breast cancer stem cells through targeting TRIM14

Axillary management after neoadjuvant therapy for breast cancer and optimization of sentinel lymph node diagnosis and treatment

Related Author

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

LU Ye

ZHANG Wenxiang

KONG Xiangyi

FANG Yi

WANG Jing

GAO Jidong

Related Institution

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Shanghai Engineering Research Center of Artificial Intelligence Technology for Tumor Diseases

Department of Laboratory Medicine, Xingtai People’s Hospital

AI问答

⁰